The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

PIK3R1 (p85α; UniProt P27986): Functional-Annotation Research Report

Executive summary

Human PIK3R1 encodes the approximately 85-kDa phosphatidylinositol 3-kinase regulatory subunit α (p85α) and the shorter splice products p55α and p50α. The identity supplied by the user—Homo sapiens, UniProt P27986, PIK3R1/GRB1, PI3K p85 family—is fully consistent with the literature; no symbol ambiguity or evidence for a different organism or protein was encountered. PIK3R1 should not be confused with PIK3CA, which encodes catalytic p110α, or PIK3R2, which encodes p85β. (donini2011thephosphatidylinositol3kinase pages 17-23, fox2020classiapi3k pages 1-3)

The principal function of p85α is noncatalytic regulation and spatial recruitment of class IA PI3K. It stabilizes p110α, p110β, or p110δ, restrains basal lipid-kinase activity, and couples the heterodimer to phosphorylated receptors and adaptor proteins. The associated p110—not p85α—phosphorylates the D3 hydroxyl of membrane phosphatidylinositol-4,5-bisphosphate [PI(4,5)P₂], producing phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P₃]. PIP₃ then recruits PH-domain proteins, notably AKT-pathway components, to the membrane. Thus, p85α is best annotated as a regulated scaffold/adaptor and allosteric inhibitor–activator switch rather than as an enzyme. (dornan2020defininghowoncogenic pages 1-2, fox2020classiapi3k pages 1-3, dornan2018molecularmechanismsof pages 1-2)

1. Identity, family, isoforms, and domain organization

PIK3R1 is the human gene for p85α and, through alternative promoters/splicing, the shorter p55α and p50α regulatory isoforms. These proteins belong to the class IA PI3K p85 regulatory-subunit family. Full-length p85α has N-terminal SH3, proline-rich, and BCR-homology/RhoGAP-like (BH) modules, followed by a C-terminal nSH2–iSH2–cSH2 regulatory cassette. The iSH2 is an antiparallel coiled coil and the major high-affinity p110-binding region; the nSH2 and cSH2 recognize phosphotyrosine motifs and contribute isoform-dependent inhibitory contacts with p110. (donini2011thephosphatidylinositol3kinase pages 17-23, fox2020classiapi3k pages 1-3, dornan2018molecularmechanismsof pages 1-2)

This organization agrees with the domains supplied in the query: the p85α SH3, nSH2, iSH2/ISH2_PIK3R1, and cSH2 modules are all represented in experimentally studied p85α. Recent structural analysis places the nSH2 approximately at residues 317–430 and iSH2 at residues 440–600, consistent with pathogenic variants clustering at p85α–p110 regulatory interfaces. (dsouza2024structuralanddynamic pages 2-3)

Table: Concise evidence matrix linking human PIK3R1/p85α identity and mechanism to structural variants, recent vascular-malformation data, and a precision-treatment case. It also distinguishes established findings from key evidentiary limitations.

2. Primary molecular function

2.1 Stabilization and basal inhibition of p110

Class IA PI3K is an obligate heterodimer containing a p110 catalytic subunit and a p85-family regulatory subunit. Binding of the p110 adaptor-binding domain to p85α iSH2 stabilizes p110, which is otherwise intrinsically unstable. At the same time, p85α maintains low basal activity through several inhibitory interfaces, including p110 C2–iSH2 contacts and nSH2 contacts with p110 C2, helical, and kinase-lobe regions. cSH2 provides additional inhibition, particularly for p110β and p110δ. This dual action—stabilization plus autoinhibition—is central to p85α function. (dornan2020defininghowoncogenic pages 1-2, dornan2018molecularmechanismsof pages 1-2)

2.2 Receptor coupling and substrate access

After receptor tyrosine kinase activation, p85α SH2 domains recognize phosphorylated YXXM motifs on receptors or adaptors such as insulin-receptor substrates. Phosphotyrosine engagement relieves inhibitory p85α–p110 contacts while recruiting the heterodimer to the cytoplasmic membrane surface, near PI(4,5)P₂. This combines an allosteric activation step with spatial access to lipid substrate. (donini2011thephosphatidylinositol3kinase pages 17-23, dornan2020defininghowoncogenic pages 1-2, fox2020classiapi3k pages 1-3)

The regulated reaction is:

PI(4,5)P₂ + ATP → PI(3,4,5)P₃ + ADP

The catalytic activity belongs to p110; p85α neither transfers phosphate nor has a known catalytic substrate specificity of its own. PIP₃ serves as a membrane second messenger that recruits AKT and other PH-domain proteins, thereby controlling survival, growth, proliferation, metabolism, cytoskeletal remodeling, trafficking, and motility. (fox2020classiapi3k pages 1-3, dornan2018molecularmechanismsof pages 1-2)

3. Cellular localization

PIK3R1 does not encode a constitutively membrane-embedded protein. The p85α–p110 complex is principally soluble/cytosolic before stimulation and is transiently recruited to the cytoplasmic face of plasma or internal membranes bearing activated phosphotyrosine receptors or adaptors. Its physiologically decisive lipid-kinase regulatory function therefore occurs at membrane–cytosol interfaces, where p110 can access PI(4,5)P₂. (donini2011thephosphatidylinositol3kinase pages 17-23, fox2020classiapi3k pages 1-3, lanahan2022theroleof pages 1-4)

Localization is context-dependent. Free p85α can associate with endocytic compartments through Rab4/Rab5 and participate in vesicle sorting and receptor down-regulation. Nuclear or nucleocytoplasmic functions have also been reported, including regulation of XBP1 nuclear translocation during the unfolded-protein response. Consequently, a single static localization label would be misleading: cytosolic with signal-dependent membrane recruitment is the most informative canonical annotation, supplemented by endosomal and nuclear/stress-related pools. (fox2020classiapi3k pages 16-18)

4. PI3K-independent adaptor functions

Cellular p85-family regulatory subunits can exist in excess of p110, leaving a free p85α pool in a monomer–dimer equilibrium. Free p85α can compete for receptor phosphotyrosines or IRS-1 binding sites and thereby raise the activation threshold for PI3K. It also interacts with and supports PTEN stability/activity, providing a second means of reducing PIP₃. (fox2020classiapi3k pages 16-18)

The N-terminal SH3/BH region mediates additional adaptor functions. The BH domain binds Cdc42, Rac1, Rab4, and Rab5; reported GAP-related effects on Rab4/Rab5 connect p85α to endocytic trafficking, vesicle sorting, and receptor down-regulation. Other p110-independent activities include cytoskeletal remodeling and migration, cytokinesis, JNK-related stress signaling, TNF-α expression, p53-dependent senescence, glucose-homeostasis responses, and XBP1 trafficking in endoplasmic-reticulum stress. These functions are mechanistically credible but generally less completely resolved than the canonical p85α–p110 pathway. (fox2020classiapi3k pages 16-18)

5. Biological pathways

Growth-factor and insulin signaling

In growth-factor and insulin pathways, receptor phosphorylation creates YXXM docking sites directly or on IRS proteins. Recruitment of p85α–p110 produces PIP₃, enabling AKT-pathway activation and downstream regulation of glucose handling, biosynthesis, growth, and survival. Stoichiometry is important: excess free p85α can compete with catalytically competent heterodimers for IRS docking sites, whereas too little regulatory subunit destabilizes p110. This helps explain why tissue-specific Pik3r1 deletion or overexpression can produce apparently opposing metabolic effects. (fox2020classiapi3k pages 16-18, kim2024divergentrolesof pages 9-10)

A 2024 review emphasizes this context dependence: whole-body or liver-specific Pik3r1 deletion can improve insulin sensitivity in mice, whereas skeletal-muscle deletion has not consistently produced the same effect; combined depletion of regulatory subunits can instead impair signaling. These observations argue against labeling p85α simply as either a positive or negative insulin-signaling factor. Its net effect depends on tissue, isoform balance, nutrient state, and the free-p85:p110-holoenzyme ratio. [Kim et al., published January 2024, DOI: https://doi.org/10.3389/fendo.2023.1152579] (kim2024divergentrolesof pages 9-10)

Immune signaling

PIK3R1 is especially important in lymphocyte class IA PI3K signaling. Human genetics associates biallelic loss with B-cell deficiency/agammaglobulinemia, whereas heterozygous activating alterations can cause activated PI3Kδ syndrome type 2/immunodeficiency with lymphoproliferation. Open Targets independently aggregates strong disease associations with SHORT syndrome, autosomal agammaglobulinemia, agammaglobulinemia 7, immunodeficiency 36 with lymphoproliferation, and cancer. (OpenTargets Search: -PIK3R1, lanahan2022theroleof pages 1-4)

6. Structure–function evidence from pathogenic variants

PIK3R1 variants do not all have the same functional direction. Their effect depends on which p85α–p110 interface is changed:

• The oncogenic iSH2 truncation Q572* disrupts multiple inhibitory inputs and hyperactivates p110α more strongly than p110δ.
• The developmental-disorder cSH2 variant R649W reduces responsiveness to receptor phosphotyrosines and therefore decreases receptor-driven activation.
• Cancer mutations at the C2–iSH2 or nSH2–p110 interfaces can release autoinhibition while retaining sufficient p110 stabilization.

These conclusions are supported by biochemical assays and hydrogen–deuterium exchange mass spectrometry rather than sequence inference alone. [Dornan et al., published February 2020, DOI: https://doi.org/10.1016/j.str.2019.11.013] (dornan2020defininghowoncogenic pages 1-2, dornan2018molecularmechanismsof pages 1-2)

The disease spectrum therefore spans opposite signaling states. Activating or disinhibitory variants contribute to cancer, overgrowth/vascular anomalies, inflammatory phenotypes, and APDS2; variants that impair receptor coupling or productive p110 stabilization can cause SHORT syndrome/undergrowth; severe biallelic loss can compromise B-cell development. PIK3R1 can consequently behave as a tumor suppressor when intact p85α restrains p110, although particular neomorphic mutations may produce additional oncogenic outputs. (OpenTargets Search: -PIK3R1, dornan2020defininghowoncogenic pages 1-2, sheng2024molecularbasisof pages 37-38, lanahan2022theroleof pages 1-4)

7. Recent developments, 2023–2024

7.1 Structural unification of undergrowth, overgrowth, and cancer variants (2024)

Dsouza et al. analyzed PIK3R1 variants using molecular modeling, energy calculations, and molecular-dynamics simulations. Their cohort included 17 patients from three institutions, with many mosaic variants below 10% allele fraction. The simulations support a unifying interface model: loss of inhibitory SH2 contacts tends to increase PI3K activity and growth, whereas destabilization of productive iSH2–PIK3CA receptor-binding-domain contacts can reduce activity and produce undergrowth. SHORT-syndrome variants F487S/E489K were predicted to destabilize iSH2 interactions, while overgrowth-associated substitutions had heterogeneous effects on SH2 docking and intermolecular energetics. [Published February 2024, DOI: https://doi.org/10.3390/life14030297] (dsouza2024structuralanddynamic pages 7-9, dsouza2024structuralanddynamic pages 2-3, dsouza2024structuralanddynamic pages 11-12)

This study advances mechanistic variant interpretation, but its molecular-dynamics predictions are not equivalent to functional validation in human cells. Some individual variant effects also differed depending on which interface or energetic metric was examined, underscoring the need for biochemical and cellular confirmation. (dsouza2024structuralanddynamic pages 7-9, dsouza2024structuralanddynamic pages 11-12)

7.2 Capillary malformation with dilated veins (2024)

De Bortoli et al. sequenced 82 capillary-malformation lesions and found nine lesions/patients with relevant somatic PIK3R1 or PIK3CA alterations: four distinct PIK3R1 variants in five patients and three noncanonical PIK3CA variants in four patients. Variant allele frequencies were 3–18%, consistent with somatic mosaicism. PIK3R1 variants affected nSH2 or iSH2 regions. Primary endothelial cells from two PIK3R1-mutant lesions showed elevated AKT phosphorylation; inhibitors of AKT, mTOR, or PIK3CA reduced the abnormal signal. Endothelial expression of mutant PIK3R1 also disrupted capillary–venous plexus development in zebrafish. [Published September 2024, DOI: https://doi.org/10.1016/j.jid.2024.01.033] (bortoli2024somaticlossoffunctionpik3r1 pages 1-2)

Three reported substitutions—G376R, N564D, and L573P—were among the 20 most recurrent of 1,663 PIK3R1 variants catalogued in cancers, connecting mosaic vascular disease to oncogenic regulatory interfaces. The study supplies human-lesion, primary-cell, inhibitor, and animal evidence, but did not report pathway-directed treatment outcomes in patients. (bortoli2024somaticlossoffunctionpik3r1 pages 1-2)

7.3 Neutrophil-restricted Sweet syndrome and precision treatment (2023)

Bhattacharya et al. studied a 51-year-old woman with refractory multiorgan Sweet syndrome and identified a neutrophil-restricted somatic PIK3R1 p.W335C gain-of-function variant. Patient and engineered-cell evidence connected the variant to elevated AKT-S473/mTORC2 signaling, increased IL-1R1, enhanced respiratory burst, and increased neutrophil migration toward IL-1β; S6/mTORC1 signaling was not similarly increased. The mutation was detected in neutrophils but not primary macrophages or sampled skin, indicating lineage restriction and a differentiation-dependent phenotype. [Published January 2023, DOI: https://doi.org/10.1172/JCI162137] (bhattacharya2023identificationofa pages 2-4, bhattacharya2023identificationofa pages 5-6)

Transcriptomic profiling compared three patient lesions with seven other Sweet syndrome patients and 13 healthy controls; 1,622 genes met the differential-expression criteria (FDR <0.1 and fold change >1.5 or <−1.5). Laser-capture sequencing initially identified 71 neutrophil-specific coding variants before prioritization of PIK3R1. (bhattacharya2023identificationofa pages 2-4)

Mechanism-guided treatment with the IL-1 receptor antagonist anakinra produced complete remission and enabled corticosteroid discontinuation. Symptoms recurred within days after treatment interruption and resolved again upon restarting; the patient remained flare- and hospitalization-free for more than three years. This is compelling real-world proof of principle for molecular stratification, but it remains a single-patient observation and does not establish general efficacy for Sweet syndrome or all PIK3R1 variants. (bhattacharya2023identificationofa pages 1-2, bhattacharya2023identificationofa pages 5-6)

8. Cancer relevance and therapeutic applications

PIK3R1 mutations have been documented across endometrial, colorectal, breast, pancreatic, bladder, and other tumors. An earlier structural synthesis mapped 884 p110α/p85α exon mutations across ten cancer types, demonstrating broad alteration of the PI3K regulatory apparatus, although that count combines PIK3CA and PIK3R1 and should not be interpreted as a PIK3R1-only prevalence estimate. (fox2020classiapi3k pages 1-3, liu2014thestructuralbasis pages 9-9)

Current clinical exploitation is predominantly pathway-directed rather than p85α-selective. Depending on whether a variant activates p110α, p110δ, AKT/mTOR, receptor feedback, MAPK, or an inflammatory effector, rational options may include PI3K-, AKT-, mTOR-, RTK-, or cytokine-pathway inhibition. For example, PIK3R1-mutant endothelial signaling was pharmacologically suppressible in vitro, and the Sweet syndrome case was successfully treated downstream with an IL-1R1 antagonist. However, the gathered evidence did not identify an approved drug that directly and selectively targets p85α. (bortoli2024somaticlossoffunctionpik3r1 pages 1-2, bhattacharya2023identificationofa pages 5-6)

PIK3R1 status is therefore most useful at present as a mechanistic biomarker requiring variant-level interpretation. A truncation that removes inhibitory contacts, a cSH2 variant that blocks receptor activation, biallelic loss, and a lineage-restricted neomorph should not be assigned the same therapeutic meaning.

9. Expert assessment and confidence

The most strongly established annotation is that p85α is the stabilizing, inhibitory, receptor-coupling regulatory subunit of class IA PI3K, with signal-dependent recruitment to membrane phosphoinositide substrate. This conclusion rests on convergent structural, biochemical, genetic, and cellular evidence. The exact lipid reaction belongs to p110 and should not be annotated as intrinsic PIK3R1 enzymatic activity. (dornan2020defininghowoncogenic pages 1-2, fox2020classiapi3k pages 1-3, dornan2018molecularmechanismsof pages 1-2)

Evidence for free-p85α adaptor functions is substantial but more context-dependent. PTEN regulation, competition for receptor/IRS sites, endocytic Rab interactions, and stress responses are biologically plausible and experimentally supported, yet their relative importance varies by cell type and p85:p110 stoichiometry. (fox2020classiapi3k pages 16-18)

The 2023–2024 literature increasingly treats PIK3R1 disease as an allelic and cellular-context spectrum, not a simple loss- versus gain-of-function gene. Recent vascular-anomaly cohorts and the Sweet syndrome case extend PIK3R1 beyond conventional cancer, metabolism, and immunodeficiency categories, while molecular simulations offer testable hypotheses for rare variants. The translational promise is meaningful, but most variant-specific evidence still comes from small cohorts, computational models, engineered cells, or individual cases. (bortoli2024somaticlossoffunctionpik3r1 pages 1-2, dsouza2024structuralanddynamic pages 7-9, bhattacharya2023identificationofa pages 1-2)

Conclusion

The appropriate functional annotation for human PIK3R1/P27986 is: a cytosolic and signal-recruited class IA PI3K regulatory/adaptor protein that stabilizes and basally inhibits p110 catalytic subunits, recognizes receptor/adaptor phosphotyrosine motifs, and positions/allosterically activates the holoenzyme at membrane PI(4,5)P₂. Its associated p110 converts PI(4,5)P₂ to PI(3,4,5)P₃, initiating AKT-centered signaling. Additional p110-independent roles connect p85α to PTEN, IRS competition, receptor trafficking, small GTPases, stress responses, and nuclear signaling. Pathogenic variants can either release inhibition, impair receptor activation, destabilize the holoenzyme, or create lineage-specific neomorphic signaling, explaining the broad spectrum from cancer and overgrowth to SHORT syndrome, immunodeficiency, vascular malformations, and inflammatory disease.

References

1. (donini2011thephosphatidylinositol3kinase pages 17-23): CF Donini. The phosphatidylinositol 3-kinase p85alpha is the physical link between camp-pka and retinoic receptor trasduction pathways. Unknown journal, 2011.

2. (fox2020classiapi3k pages 1-3): Millie Fox, Helen R. Mott, and Darerca Owen. Class ia pi3k regulatory subunits: p110-independent roles and structures. Biochemical Society Transactions, 48:1397-1417, Jul 2020. URL: https://doi.org/10.1042/bst20190845, doi:10.1042/bst20190845. This article has 109 citations and is from a peer-reviewed journal.

3. (dornan2020defininghowoncogenic pages 1-2): Gillian L. Dornan, Jordan T.B. Stariha, Manoj K. Rathinaswamy, Cameron J. Powell, Martin J. Boulanger, and John E. Burke. Defining how oncogenic and developmental mutations of pik3r1 alter the regulation of class ia phosphoinositide 3-kinases. Structure, 28:145-156.e5, Feb 2020. URL: https://doi.org/10.1016/j.str.2019.11.013, doi:10.1016/j.str.2019.11.013. This article has 35 citations and is from a domain leading peer-reviewed journal.

4. (dornan2018molecularmechanismsof pages 1-2): Gillian L. Dornan and John E. Burke. Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in class ia phosphoinositide 3-kinases. Frontiers in Immunology, Mar 2018. URL: https://doi.org/10.3389/fimmu.2018.00575, doi:10.3389/fimmu.2018.00575. This article has 94 citations and is from a peer-reviewed journal.

5. (dsouza2024structuralanddynamic pages 2-3): Nikita R. Dsouza, Catherine E. Cottrell, Olivia M. T. Davies, Megha M. Tollefson, Ilona J. Frieden, Donald Basel, Raul Urrutia, Beth A. Drolet, and Michael T. Zimmermann. Structural and dynamic analyses of pathogenic variants in pik3r1 reveal a shared mechanism associated among cancer, undergrowth, and overgrowth syndromes. Life, 14:297, Feb 2024. URL: https://doi.org/10.3390/life14030297, doi:10.3390/life14030297. This article has 8 citations.

6. (fox2020classiapi3k pages 16-18): Millie Fox, Helen R. Mott, and Darerca Owen. Class ia pi3k regulatory subunits: p110-independent roles and structures. Biochemical Society Transactions, 48:1397-1417, Jul 2020. URL: https://doi.org/10.1042/bst20190845, doi:10.1042/bst20190845. This article has 109 citations and is from a peer-reviewed journal.

7. (bortoli2024somaticlossoffunctionpik3r1 pages 1-2): Martina De Bortoli, Angela Queisser, Van Cuong Pham, Anne Dompmartin, Raphaël Helaers, Simon Boutry, Cathy Claus, An-Katrien De Roo, Frank Hammer, Pascal Brouillard, Salim Abdelilah-Seyfried, Laurence M. Boon, and Miikka Vikkula. Somatic loss-of-function pik3r1 and activating non-hotspot pik3ca mutations associated with capillary malformation with dilated veins (cmdv). Sep 2024. URL: https://doi.org/10.1016/j.jid.2024.01.033, doi:10.1016/j.jid.2024.01.033. This article has 19 citations and is from a highest quality peer-reviewed journal.

8. (bhattacharya2023identificationofa pages 1-2): Shreya Bhattacharya, Sayon Basu, Emily Sheng, Christina Murphy, Jenny Wei, Anna E. Kersh, Caroline A. Nelson, Joshua S. Bryer, Hovik A. Ashchyan, Katherine Steele, Amy Forrestel, John T. Seykora, Robert G. Micheletti, William D. James, Misha Rosenbach, and Thomas H. Leung. Identification of a neutrophil-specific pik3r1 mutation facilitates targeted treatment in a patient with sweet syndrome. Jan 2023. URL: https://doi.org/10.1172/jci162137, doi:10.1172/jci162137. This article has 16 citations and is from a highest quality peer-reviewed journal.

9. (bhattacharya2023identificationofa pages 5-6): Shreya Bhattacharya, Sayon Basu, Emily Sheng, Christina Murphy, Jenny Wei, Anna E. Kersh, Caroline A. Nelson, Joshua S. Bryer, Hovik A. Ashchyan, Katherine Steele, Amy Forrestel, John T. Seykora, Robert G. Micheletti, William D. James, Misha Rosenbach, and Thomas H. Leung. Identification of a neutrophil-specific pik3r1 mutation facilitates targeted treatment in a patient with sweet syndrome. Jan 2023. URL: https://doi.org/10.1172/jci162137, doi:10.1172/jci162137. This article has 16 citations and is from a highest quality peer-reviewed journal.

10. (dsouza2024structuralanddynamic pages 7-9): Nikita R. Dsouza, Catherine E. Cottrell, Olivia M. T. Davies, Megha M. Tollefson, Ilona J. Frieden, Donald Basel, Raul Urrutia, Beth A. Drolet, and Michael T. Zimmermann. Structural and dynamic analyses of pathogenic variants in pik3r1 reveal a shared mechanism associated among cancer, undergrowth, and overgrowth syndromes. Life, 14:297, Feb 2024. URL: https://doi.org/10.3390/life14030297, doi:10.3390/life14030297. This article has 8 citations.

11. (lanahan2022theroleof pages 1-4): Stephen M. Lanahan, Matthias P. Wymann, and Carrie L. Lucas. The role of pi3kγ in the immune system: new insights and translational implications. Nature Reviews Immunology, 22:687-700, Mar 2022. URL: https://doi.org/10.1038/s41577-022-00701-8, doi:10.1038/s41577-022-00701-8. This article has 97 citations and is from a highest quality peer-reviewed journal.

12. (kim2024divergentrolesof pages 9-10): Cho-Won Kim, Junsik M. Lee, and Sang Won Park. Divergent roles of the regulatory subunits of class ia pi3k. Frontiers in Endocrinology, Jan 2024. URL: https://doi.org/10.3389/fendo.2023.1152579, doi:10.3389/fendo.2023.1152579. This article has 22 citations.

13. (OpenTargets Search: -PIK3R1): Open Targets Query (-PIK3R1, 9 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

14. (sheng2024molecularbasisof pages 37-38): Zhi Sheng, Patrick Beck, Maegan Gabby, Semhar Habte-Mariam, and Katherine Mitkos. Molecular basis of oncogenic pi3k proteins. Cancers, 17:77, Dec 2024. URL: https://doi.org/10.3390/cancers17010077, doi:10.3390/cancers17010077. This article has 10 citations.

15. (dsouza2024structuralanddynamic pages 11-12): Nikita R. Dsouza, Catherine E. Cottrell, Olivia M. T. Davies, Megha M. Tollefson, Ilona J. Frieden, Donald Basel, Raul Urrutia, Beth A. Drolet, and Michael T. Zimmermann. Structural and dynamic analyses of pathogenic variants in pik3r1 reveal a shared mechanism associated among cancer, undergrowth, and overgrowth syndromes. Life, 14:297, Feb 2024. URL: https://doi.org/10.3390/life14030297, doi:10.3390/life14030297. This article has 8 citations.

16. (bhattacharya2023identificationofa pages 2-4): Shreya Bhattacharya, Sayon Basu, Emily Sheng, Christina Murphy, Jenny Wei, Anna E. Kersh, Caroline A. Nelson, Joshua S. Bryer, Hovik A. Ashchyan, Katherine Steele, Amy Forrestel, John T. Seykora, Robert G. Micheletti, William D. James, Misha Rosenbach, and Thomas H. Leung. Identification of a neutrophil-specific pik3r1 mutation facilitates targeted treatment in a patient with sweet syndrome. Jan 2023. URL: https://doi.org/10.1172/jci162137, doi:10.1172/jci162137. This article has 16 citations and is from a highest quality peer-reviewed journal.

17. (liu2014thestructuralbasis pages 9-9): Shujuan Liu, Stefan Knapp, and Ahmed Ashour Ahmed. The structural basis of pi3k cancer mutations: from mechanism to therapy. Cancer research, 74 3:641-6, Feb 2014. URL: https://doi.org/10.1158/0008-5472.can-13-2319, doi:10.1158/0008-5472.can-13-2319. This article has 99 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Citations

1. dsouza2024structuralanddynamic pages 2-3
2. dornan2020defininghowoncogenic pages 1-2
3. kim2024divergentrolesof pages 9-10
4. bhattacharya2023identificationofa pages 2-4
5. dornan2018molecularmechanismsof pages 1-2
6. bhattacharya2023identificationofa pages 1-2
7. bhattacharya2023identificationofa pages 5-6
8. dsouza2024structuralanddynamic pages 7-9
9. lanahan2022theroleof pages 1-4
10. sheng2024molecularbasisof pages 37-38
11. dsouza2024structuralanddynamic pages 11-12
12. liu2014thestructuralbasis pages 9-9
13. PI(4,5)P₂
14. PI(3,4,5)P₃
15. Kim et al., published January 2024, DOI: https://doi.org/10.3389/fendo.2023.1152579
16. Dornan et al., published February 2020, DOI: https://doi.org/10.1016/j.str.2019.11.013
17. Published February 2024, DOI: https://doi.org/10.3390/life14030297
18. Published September 2024, DOI: https://doi.org/10.1016/j.jid.2024.01.033
19. Published January 2023, DOI: https://doi.org/10.1172/JCI162137
20. https://doi.org/10.3389/fendo.2023.1152579]
21. https://doi.org/10.1016/j.str.2019.11.013]
22. https://doi.org/10.3390/life14030297]
23. https://doi.org/10.1016/j.jid.2024.01.033]
24. https://doi.org/10.1172/JCI162137]
25. https://doi.org/10.1042/bst20190845,
26. https://doi.org/10.1016/j.str.2019.11.013,
27. https://doi.org/10.3389/fimmu.2018.00575,
28. https://doi.org/10.3390/life14030297,
29. https://doi.org/10.1016/j.jid.2024.01.033,
30. https://doi.org/10.1172/jci162137,
31. https://doi.org/10.1038/s41577-022-00701-8,
32. https://doi.org/10.3389/fendo.2023.1152579,
33. https://doi.org/10.3390/cancers17010077,
34. https://doi.org/10.1158/0008-5472.can-13-2319,